Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07171606
PHASE2

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients

Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

View on ClinicalTrials.gov

Summary

This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2025-10-24

Completion Date

2027-08-31

Last Updated

2025-12-18

Healthy Volunteers

No

Interventions

DRUG

SSGJ-706

PD-1/PD-L1 bispecific antibody

DRUG

pemetrexed /carboplatin

chemotherapy

DRUG

Carboplatin/Paclitaxel

chemotherapy

DRUG

PD-1 Inhibitor + Chemotherapy

control group

Locations (1)

Institute of The Shanghai Pulmonary Hospital

Shanghai, China